Ingeborg Friehs

Dr. Ingeborg Friehs

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
VWViktoria Weixler
Viktoria Weixler
RLRazvan Lapusca
Razvan Lapusca
GGGernot Grangl
Gernot Grangl
AGAlvise Guariento
Alvise Guariento
MSMossab Y. Saeed
Mossab Y. Saeed
IFIngeborg Friehs
Ingeborg Friehs

1 February 2020 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
VWViktoria Weixler
Viktoria Weixler
GMGerald R. Marx
Gerald R. Marx
PHPeter E. Hammer
Peter E. Hammer
SESitaram M. Emani
Sitaram M. Emani
PNPedro J. del Nido
Pedro J. del Nido
IFIngeborg Friehs
Ingeborg Friehs

8 October 2010 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
EKElisabeth Kaza
Elisabeth Kaza
KAKlemens Ablasser
Klemens Ablasser
DPDimitrios Poutias
Dimitrios Poutias
EGEric R. Griffiths
Eric R. Griffiths
FSFawzy A. Saad
Fawzy A. Saad
IFIngeborg Friehs
Ingeborg Friehs
Inadequate capillary growth in pressure-overload hypertrophy impairs myocardial perfusion and substrate delivery, contributing to progression to failure. Capillary growth is tightly regulated by angiogenesis growth factors like vascular endothelial growth factor (VEGF) and endogenous inhibitors such as the splice variant of VEGF receptor-1, sVEGFR-1. We hypothesized that inadequate expression of VEGF and up-regulation of VEGFR-1 and its soluble splice variant, sVEGFR-1, restrict capillary growth in pressure-overload hypertrophy. Neonatal New Zealand White rabbits underwent aortic banding. mRNA (qRT–PCR) and protein levels (immunoblotting) were determined in hypertrophied and control myocardium (7/group) for total VEGF, VEGFR-1, sVEGFR-1, VEGFR-2, and phospho-VEGFR-1 and -R-2. Free VEGF was determined by enzyme-linked immunoassay (ELISA) in hypertrophied myocardium, controls, and hypertrophied hearts following inhibition of sVEGFR-1 with placental growth factor (PlGF). VEGFR-1 and sVEGFR-1 mRNA (seven-fold up-regulation, P = 0.001) and protein levels were significantly up-regulated in hypertrophied hearts vs. controls (VEGFR-1: 44 ± 8 vs. 23 ± 1, P = 0.031; sVEGFR-1: 71 ± 13 vs. 31 ± 3, P = 0.016). There was no change in VEGF and VEGFR-2 mRNA or protein levels in hypertrophied compared with controls hearts. A significant decline in free, unbound VEGF was found in hypertrophied myocardium which was reversed following inhibition of sVEGFR-1 with PlGF, which was accompanied by phosphorylation of VEGFR-1 and VEGFR-2. Up-regulation of the soluble VEGFR-1 in pressure-loaded myocardium prevents capillary growth by trapping VEGF. Inhibition of sVEGFR-1 released sufficient VEGF to induce angiogenesis and preserved contractile function. These data suggest sVEGFR-1 as possible therapeutic targets to prevent heart failure.

1 November 2012 in The Annals of Thoracic Surgery
Verified
Journal Article
Open access
PDF file
ANAndriana Nikolova
Andriana Nikolova
KAKlemens Ablasser
Klemens Ablasser
MBMoritz C. Wyler von Ballmoos
Moritz C. Wyler von Ballmoos
DPDimitrios Poutias
Dimitrios Poutias
EKElisabeth Kaza
Elisabeth Kaza
IFIngeborg Friehs
Ingeborg Friehs
Background In left ventricular (LV) pressure-overload hypertrophy, lack of adaptive capillary growth contributes to progression to failure. Remodeling of the hypertrophied myocardium requires proteolysis of the extracellular matrix (ECM) carried out by matrix metalloproteinases (MMPs). MMPs, specifically MMP-9, are known to cleave ECM components to generate angiogenesis inhibitors (angiostatin, endostatin, tumstatin). We hypothesize that MMP-9 releases antiangiogenic factors during compensated and decompensated hypertrophy, which results in lack of adaptive capillary growth. Methods Newborn rabbits underwent aortic banding. Myocardial tissue from age-matched and banded animals at compensated (4 weeks) and decompensated hypertrophy (7 weeks), as identified by serial echocardiography, was analyzed by immunoblotting for angiostatin, endostatin, and tumstatin. MMP-9 activity was determined by zymography. A cell-permeable, potent, selective MMP-9 inhibitor was administered intrapericardially to animals with hypertrophied hearts and tissue was analyzed. Results MMP-9 is activated in hypertrophied myocardium versus in control hearts (22 ± 2 versus 16 ± 1; p = 0.04), which results in significantly increased levels of angiostatin (115 ± 10 versus 86 ± 7; p = 0.02), endostatin (33 ± 1 versus 28 ± 1; p = 0.006), and tumstatin (35 ± 6 versus 17 ± 4; p = 0.04). Zymography confirms inhibition of MMP-9 (hypertrophy + MMP-9 inhibitor, 14 ± 0.6 versus hypertrophy + vehicle, 17 ± 1; p = 0.01) and angiostatin, endostatin, and tumstatin are down-regulated, accompanied by up-regulation of capillary density (hypertrophy + MMP-9 inhibitor, 2.99 ± 0.07 versus hypertrophy + vehicle, 2.7 ± 0.05; p = 0.002). Conclusions Up-regulation of angiogenesis inhibitors prevents adaptive capillary growth in pressure-overload hypertrophied myocardium. Therapeutic interventions aimed at inhibition of angiogenesis inhibitors are useful in maintaining capillary density and thereby preventing heart failure.

1 September 2017 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
BIBen M.-W. Illigens
Ben M.-W. Illigens
ABAlejandra Casar Berazaluce
Alejandra Casar Berazaluce
DPDimitrios Poutias
Dimitrios Poutias
RGRobert Gasser
Robert Gasser
PNPedro J. del Nido
Pedro J. del Nido
IFIngeborg Friehs
Ingeborg Friehs

1 June 2013 in Journal of Surgical Research
Verified
Journal Article
Closed access
IFIngeborg Friehs
Ingeborg Friehs
BIBen Illigens
Ben Illigens
IMIvan Melnychenko
Ivan Melnychenko
TZTachi Zhong-Hu
Tachi Zhong-Hu
EZElisabeth Zeisberg
Elisabeth Zeisberg
PNPedro J. del Nido
Pedro J. del Nido